Monday, 27 June 2022


AnchorDx appoints Dr. Marina Bibikova as Chief Scientific Officer

07 March 2022 | News

Dr. Bibikova is an international leader with over 25 years of experience in genomics industry.

AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. Marina Bibikova has come on board as Chief Scientific Officer (CSO). She will be responsible for cancer early detection technology development, global IVD registrations, strategic partnerships with leading overseas companies, international patent strategy, and the acceleration of global commercialization.

Dr. Bibikova is an international leader with over 25 years of experience in genomics industry. She has published over 70 academic papers, holds 6 international patents, and has developed a series of breakthrough genetic testing technologies and products. Prior to joining AnchorDx, Dr. Bibikova worked at Illumina for over 20 years where she served as Principal Scientist, responsible for the development of both Research and IVD products, covering genotyping, gene expression profiling and DNA methylation analysis.

It is noteworthy that Dr. Bibikova led Illumina MiSeqDx sequencer 510(K) submission, which was the first in vitro diagnostic next-generation sequencing (NGS) instrument that was cleared by the U.S. FDA, and has subsequently obtained EU CE-IVD certification and China NMPA certification. It established foundation for successful registration of other sequencing platforms such as the NextSeq 550Dx. 

The Board of AnchorDx highly recognizes Dr. Bibikova's capabilities, and highlighted the fact that the internationalization of technology, products and marketing are the next major goals for the Company, which are also competitive advantages of the Company. Dr. Bibikova's solid platform, IVD product development and registration experience will bring great value to the realization of AnchorDx's global positioning and strategic implementation.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account